| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers E > Headlines for Exactech, Inc. > News item |
Exactech: FDA approves Optecure+CCC orthopedic product
By Lisa Kerner
Charlotte, N.C., Sept. 26 - Exactech, Inc. said the Food and Drug Administration granted 510(k) clearance for a new formulation of the company's Optecure allograft, Optecure+CCC, for use as a bone graft extender in the extremities, spine and pelvis as well as a bone void filler.
"The Optecure+CCC formulation contains osteoconductive bone chips, providing surgeons with a wider range of products for application-specific solutions," senior vice president and general manager Bruce Thompson said in a news release.
Based in Gainesville, Fla., Exactech develops orthopedic implant devices, related surgical instruments and biologic materials.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.